US Stock Activity: Summit Therapeutics surged on October 19 due to phase II kidney cancer trial and cooperation with Akeso
Bitget异动解读2026/10/19 15:30Summit Therapeutics Soars on October 19: Analysis
Keywords: Renal cancer Phase II trial, Akeso collaboration
1. On October 19, Summit announced the initiation and opening of a multi-regional randomized Phase II clinical study in partnership with Akeso, aiming to enroll approximately 100 clear cell renal cancer patients who have not previously received systemic therapy for advanced disease. The trial centers are located in the United States and China.
2. The trial protocol released on October 19 evaluates ivonescimab as monotherapy, in combination with cadonilimab or ipilimumab, and uses nivolumab combined with ipilimumab as the standard treatment control arm. Ivonescimab is the company's PD-1/VEGF bispecific antibody in development.
(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hassett: U.S. inflation still requires attention, respect for the Federal Reserve's independence is essential
White House National Economic Council Director Hassett stated on Monday that the U.S. September CPI data may suggest a disruption in the downward trend of inflation, or it could just be a temporary fluctuation. He emphasized that overall inflation remains an issue that requires attention at the policy level. He reiterated respect for the Federal Reserve’s independence, saying that Waller would “do what he believes is right.” He also noted that people are optimistic about the U.S. economy and that consumption is increasing.
Nscale's IPO outlook boosted with Nvidia's support; Report: In talks with Anthropic on a $45 billion deal
If the agreement is implemented, the total scale of cooperation between the two parties will reach $90 billions. The relevant negotiations involve the second building of the Monarch data center campus, which provides 460MW of computing power and adopts NVIDIA’s latest generation Vera Rubin chips. In addition, Anthropic has also obtained the priority negotiation rights for the third building in the Monarch campus plan.
Nasdaq rose 1.11%, Amazon surged 4.98% and led the top trading volume stocks.
Crypto prices
More
